Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Repoxygen
Другие языки:

Repoxygen

Подписчиков: 0, рейтинг: 0

Repoxygen was the tradename for a type of gene therapy to produce erythropoietin (EPO). It was under preclinical development by Oxford Biomedica as a possible treatment for anaemia but was abandoned in 2003.

The project became infamous when it was mentioned during the criminal trial of Thomas Springstein, a former track coach for some German athletes, who was found guilty of giving athletes performance enhancing drugs without their knowledge. An email in which Springstein attempted to obtain Repoxygen was read by a prosecutor, which led to a flurry of media coverage.

The World Anti-Doping Agency banned "gene doping" in 2003 and as of 2009 was researching detection methods for substances such as repoxygen.

Further reading

  • Patrick Barry. Aug. 2, 2008 Finding the Golden Genes. Science News 174(3):16-21
  • Yoshimi M, Maeyama T, Yamada M, Hamada N, Fukumoto J, Kawaguchi T, Kuwano K, & Nakanishi Y. (2008). Recombinant human erythropoietin reduces epithelial cell apoptosis and attenuates bleomycin-induced pneumonitis in mice. Respirology 13(5). 639-645.
  • Percy MJ. (2008). Familial erythrocytosis arising from a gain-of-function mutation in the HIF2A gene of the oxygen sensing pathway. Ulster Medical Journal 77(2). 86-88.

Новое сообщение